ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: opioid

Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment

Ruth Jessen Hickman, MD  |  October 1, 2020

A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…

Filed under:Drug UpdatesOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyfasinumabKnee Osteoarthritis (OA)Nerve growth factor (NGF)osteoarthritis (OA)tanezumab

FDA Receives Upadacitinib Application for Ankylosing Spondylitis & Approves Tramadol Hydrochloride Oral Solution

Michele B. Kaufman, PharmD, BCGP  |  September 30, 2020

In August, Abbvie submitted a new drug application for upadacitinib to treat ankylosing spondylitis. And in September, the FDA approved an oral solution of tramadol hydrochloride for pain.

Filed under:Axial SpondyloarthritisDrug Updates Tagged with:Ankylosing SpondylitisAS Resource CenterFDAPainPain Managementtramadol hydrochlorideU.S. Food and Drug Administration (FDA)upadacitinib

Dorothy.Wedel / shutterstock.com

How Duke’s School of Medicine Implemented a Quality Improvement Curriculum

Lisa Criscione-Schreiber, MD, MEd, Ryan Jessee, MD, & David Leverenz, MD  |  July 15, 2020

It has been about 20 years since the Institute of Medicine (now the National Academy of Medicine) published the report To Err Is Human: Building a Safer Health System, shining light on the impact of medical errors in healthcare.1 In response to that publication, the focus on quality improvement (QI) started in the inpatient setting,…

Filed under:Education & TrainingPractice SupportQuality Assurance/Improvement Tagged with:curriculum

Lemau Studio / shutterstock.com

Tips for Understanding the Pathways of Pain & Choosing Treatments

Carina Stanton  |  May 15, 2020

SNOWMASS VILLAGE, COLO.—The science underlying the neurobiology of chronic pain isn’t something rheumatologists often think about. However, pain is an important reason why patients see a rheumatologist. At the 2020 ACR Winter Symposium in January, Leslie Crofford, MD, gave two presentations addressing pain experienced by rheumatology patients, including a session on the fundamental mechanisms of…

Filed under:AnalgesicsConditions Tagged with:Pain Managementpain mechanismspain pathwaysWinter Rheumatology Summit

FDA Considers Tanezumab Application for Chronic OA Pain

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2020

The FDA is considering an application for subcutaneous tanezumab, a monoclonal antibody, as a treatment for moderate to severe osteoarthritis…

Filed under:AnalgesicsConditionsDrug UpdatesPain Syndromes Tagged with:Chronic painFDAosteoarthritis (OA)PainPain ManagementtanezumabU.S. Food and Drug Administration (FDA)

Experts Offer Tips for Saving Time on Electronic Medical Records

Thomas R. Collins  |  April 15, 2020

ATLANTA—“Bane of our existence” and “pajama time”—the dreaded time spent at night catching up on documentation—are a couple of phrases associated with the electronic medical record (EMR). To try to ease the frustration and limit the amount of time physicians have to spend using the systems, two experts reviewed tools and tricks for Epic and…

Filed under:EMRsMeeting ReportsTechnology Tagged with:2019 ACR/ARP Annual Meeting

A Public Health Approach to Arthritis

Thomas R. Collins  |  March 12, 2020

ATLANTA—Rheumatic diseases have been the subject of a range of public health campaigns and reports over the past decade, but improving their visibility remains a work in progress, a Centers for Disease Control and Prevention (CDC) expert said at the 2019 ACR/ARP Annual Meeting. A growing attention to pain and the opioid crisis may help…

Filed under:AnalgesicsConditionsMeeting Reports Tagged with:2019 ACR/ARP Annual MeetingCenters for Disease Control and Preventionopioid crisisPain Managementpublic health

FDA Advisory Committees Reject Oxycodegol (NKTR-181) Application

Michele B. Kaufman, PharmD, BCGP  |  February 19, 2020

FDA advisory committees rejected the new drug application for oxycodegol, an opioid analgesic, due to a lack of data regarding it’s potential for abuse…

Filed under:AnalgesicsDrug Updates Tagged with:FDANKTR-181opioidoxycodegolPain ManagementU.S. Food and Drug Administration (FDA)

A Public Health Approach to Arthritis: Experts Continue to Raise Awareness of Arthritis Burden

Thomas R. Collins  |  February 12, 2020

Public health agencies have been raising the profile of arthritis…

Filed under:Professional Topics Tagged with:ArthritisburdenCDCpublic health

New Gabapentinoid Warning Labels

Michele B. Kaufman, PharmD, BCGP  |  January 23, 2020

Gabapentinoid products will now carry warning labels about the risks of respiratory distress when combined with opioids and other nervous system and respiratory depressants…

Filed under:Uncategorized Tagged with:Drug SafetyFDAgabapentinoidsU.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 11
  • 12
  • 13
  • 14
  • 15
  • …
  • 32
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences